SAN DIEGO, BioNano Genomics, Inc. has hired Garth Monroe as the company’s new chief financial officer. Mr. Monroe joins BioNano Genomics’ senior management team, and reports to President and Chief Executive Officer Dr. R. Erik Holmlin. BioNano Genomics combines the latest in biotech and nanotech to deliver an altogether better way of gaining a fully informed understanding of genomes.

“Bringing Garth aboard is the next step in the evolution of BioNano Genomics as a solution provider for researchers who want to fully understand the biology of the genomes at the core of their research,” said BioNano Genomics President and CEO Dr. R. Erik Holmlin. “He will provide considerable financial leadership to our company as we commercialize and grow.”

Prior to joining BioNano Genomics, Mr. Monroe served as CFO for Epocal, a multi-national, venture-backed medical device company. There, he played an integral role in the $255 million sale of the company to Alere™. Mr. Monroe previously served as station manager for JetBlue Airways and a financial analyst at United Technologies. He is a certified public accountant and holds a Bachelor of Science in Business Administration from the University of Connecticut and a Master of Business Administration from the University of Virginia, Darden School of Business.

“I am very enthusiastic about the opportunity to help Bionano Genomics carry out the vision for financial growth and commercialization,” added Mr. Monroe.

About BioNano Genomics

Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company’s nanoAnalyzer platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by grants from genomics programs at agencies, including the NIH and NIST-ATP.